| Real time
12:26:11 01/07/2024 | It varies. 5j. | Varia. Jan 1 | ||
| 4,85 | +8,99 % | +21,49 % | -26,96 % | |
July 1, 2024 at 12:21 p.m.
The biotech company is leading the SRD market on Monday after losing more than 9% on Friday. The stock is still down 24% since the start of the year.
© AOF – 2024
| Nanobiotix: biggest increase in the SRD market at mid-session on Monday, July 1, 2024 | 12:21 | TO THE |
| Nanobiotix: biggest increase in the SRD market at the close of Wednesday, June 26, 2024 | 26/06 | TO THE |
| Actions on the move: Alfen and the Deliveroo / DoorDash and Volkswagen / Rivian duos | 26/06 | |
| Nanobiotix: largest increase in the SRD market at mid-session on Wednesday June 26, 2024 | 26/06 | TO THE |
| Nanobiotix: well-oriented on broker’s remarks | 25/06 | CF |
| NANOBIOTIX: Stifel initiates buy coverage | 25/06 | CF |
| Badaboum | 25/06 | |
| ANALYST OPINION OF THE DAY: Airbus, Kering, Danone, AB Inbev, ArgenX, Nestlé, Nexans, Trigano… | 25/06 | |
| Transcript : Nanobiotix S.A. – Special Call | 18/06 | |
| ANALYST OPINION OF THE DAY: Air Liquide, Renault, Rémy Cointreau, Barry Callebaut, Fluidra, Rexel… | 10/06 |  |
| Nanobiotix: positive results for NBTXR3 | 03/06 | TO THE |
| Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated with NBTXR3 Activated by Radiotherapy Followed by Anti-PD-1 for 2l+ R/M HNSCC Naive or Resistant to Prior Anti-PD-1 Therapy | 03/06 | CI |
| Make us dream, Christine | 03/06 | |
| Live from the Markets: Sanofi, Airbus, Thales, Atos, Casino, Tesla, Aramco, Valneva… | 03/06 | |
| Transcript : Nanobiotix S.A. – Special Call | 02/06 | |
| Nvidia close to committing a crime against Apple | 29/05 | |
| Live from the Markets: Bouygues, Michelin, Volkswagen, BHP, ConocoPhillips, BYD, Casino… | 29/05 | |
| Nanobiotix SA announces presentation of new data from Phase 1 immunotherapy program at the 2024 American Society for Clinical Oncology Annual Meeting. | 28/05 | CI |
| Nanobiotix: biggest drop in the SRD at the close of Wednesday, May 22, 2024 – | 22/05 | TO THE |
| Transcript : Nanobiotix S.A., Q1 2024 Earnings Call, May 22, 2024 | 22/05 | |
| Nanobiotix: strategy update, stock declines | 22/05 | CF |
| Nanobiotix: €58.9 million in cash as of March 31, visibility until the 3rd quarter of 2025 | 22/05 | TO THE |
| You-know-who is posting tonight | 22/05 | |
| Live from the Markets: Schneider, TotalEnergies, LVMH, BBVA, Amazon, Nvidia, Snowflake… | 22/05 | |
| Nanobiotix Transfers Sponsorship of Phase 3 Head and Neck Cancer Study | 21/05 | MT |
Duration Auto. 2 months 3 months 6 months 9 months 1 an 2 ans 5 ans 10 ans Max.
Period Jour Week
More graphics
Nanobiotix is a pioneer and leader in nanomedicine with a revolutionary approach to the treatment of cancer. The Company is focused on the development of its fully patented NanoXray product portfolio, an innovation based on the physical mode of action of nanoparticles that, when exposed to radiotherapy, maximize the absorption of X-rays inside cancer cells without increasing the doses received by surrounding healthy tissues. NanoXray products are compatible with standard radiotherapy treatments and are intended to potentially treat a wide variety of cancers via multiple routes of administration. The Company’s resources are primarily dedicated to the development of its lead product candidate NBTXR3, which is the product of its proprietary oncology platform and which has already obtained marketing authorization in Europe for the treatment of patients with soft tissue sarcomas under the brand name Hensify®.
More information about the company
Purchase
Average recommendation
ACHETER
Last Closing Price
4,45
EUR
Average course objective
11,68
EUR
Gap / Average Objective
+162,47 %
Consensus
| Varia. Jan 1 | Capi. | |
|---|---|---|
| -27,26 % | 225 M | |
| +19,41 % | 45,51 Md | |
| -8,62 % | 38,52 Md | |
| +38,99 % | 38,13 Md | |
| +26,95 % | 30,74 Md | |
| -13,50 % | 26,03 Md | |
| +10,74 % | 25,92 Md | |
| +44,87 % | 14,13 Md | |
| +34,36 % | 12,73 Md | |
| -7,14 % | 11,29 Md |
Biotechnological and medical research – Others
